Showing 7611-7620 of 9326 results for "".
- Combined Ultrasound and Radiofrequency Promotes Greater Wrinkle Reductionhttps://practicaldermatology.com/news/combined-ultrasound-and-radiofrequency-promotes-greater-wrinkle-reduction/2462721/Using high-intensity focused ultrasound in conjunction with monopolar radiofrequency yielded greater skin tightening and wrinkle reduction than either modality alone, according to new data. High-intensity focused ultrasound (HIFU) and monopolar radiofrequency (RF) are both popular as non-
- Study Highlights Dermatology Resident Views on Sensitive Skin Educationhttps://practicaldermatology.com/news/study-highlights-dermatology-resident-views-sensitive-skin-education/2462717/In a recent article published in the Journal of Drugs in Dermatology, researchers shed light on the educational exposure and perspectives of dermatology resident physicians regarding sensitive skin. Sensitive skin, typified by symptoms such as redness, itching, burning, and sting
- Mechanical Micro-Coring Shows Promise for Neck Treatmenthttps://practicaldermatology.com/news/aslms-2024-mechanical-micro-coring-shows-promise-neck-treatment/2462716/Mechanical dermal micro-coring is a safe and effective option for improving skin laxity, texture, and wrinkles on the neck, based on new data appearing at the American Society for Laser Medicine and Surgery (ASLMS) 43rd Annual Conference on Energy-based Medicine and Science in Baltimor
- New Data Show Efficacy of Topical 0.1% Stabilized Bioactive Retinol for Photoaginghttps://practicaldermatology.com/news/analysis-data-shows-efficacy-topical-01-stabilized-bioactive-retinol-photoaging/2462643/A recent integrated analysis published in the Journal of Drugs in Dermatology showed the efficacy and tolerability of topical 0.1% stabilized bioactive retinol in countering the signs of photoaging. "Advances in formulation science have allowed the production of stabilized bioact
- Gene Variants May Drive Persistent Lesions in Darier Diseasehttps://practicaldermatology.com/news/gene-variants-may-drive-persistent-lesions-darier-disease/2462509/Persistent lesions in patients with Darier disease were associated with second-hit variants in the ATP2A2 gene, according to data from a new case series of 9 patients. In a study published in JAMA Dermatology, Lihi Atzmony, MD, of Rabin Medical Center, Petach Tikva, Israel, and c
- Updated Coding Curbs Complex Repair Billing by Mohs Surgeonshttps://practicaldermatology.com/news/updated-coding-curbs-complex-repair-billing-mohs-surgeons/2462489/Complex repairs billed by Mohs surgeons decreased significantly from 2019 to 2021 in the wake of new coding guidelines, according to a national Medicare analysis. Publishing in Dermatologic Surgery, Christian Gronbeck, MD, of the University of Connecticut, Farmington, and colleag
- LEO Foundation Plans to Double Philanthropic Grants for Skin Diseaseshttps://practicaldermatology.com/news/leo-foundation-plans-double-philanthropic-grants-skin-diseases/2462483/Reporting a successful year in 2023, the LEO Foundation has announced its goals and aspirations out to 2030, including the awarding of a prestigious 5 million Danish kroner prize to a distinguished researcher in Denmark contributing to skin research. The Foundation plans to double its phi
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A
- Ted Danson Partners with Bristol Myers Squibb for Plaque Psoriasis Campaignhttps://practicaldermatology.com/news/ted-danson-partners-with-bristol-myers-squibb-for-plaque-psoriasis-campaign/2462442/Bristol Myers Squibb has partnered with award-winning actor Ted Danson, who lives with plaque psoriasis, for a new campaign called “
- Ruxolitinib Cream 1.5% Effective in Hidradenitis Suppurativa Hurley Stage 1 or 2 Patientshttps://practicaldermatology.com/news/ruxolitinib-cream-15-shows-efficacy-for-hidradenitis-suppurativa-hurley-stage-1-or-2-patients/2462427/Data from a new phase 2 trial indicate twice-daily ruxolitinib cream, 1.5% (OpzeluraTM, Incyte) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS) was safe and effective. The primary endpoint of the study was achieved, with patients on t